From the Department of Orthopedics & Rehabilitation, University of Wisconsin School of Medicine and Public Health, Madison, WI (Dr. Bernatz, Dr. Winzenried, Ms. Hare, Dr. Williams, and Dr. Anderson); the Department of Neurological Surgery, Mayo Clinic, Rochester, MN (Dr. Mikula); and the Divisions of Endocrinology and Geriatrics, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI (Dr. Binkley).
J Am Acad Orthop Surg Glob Res Rev. 2022 Mar 15;6(3):e21.00253. doi: 10.5435/JAAOSGlobal-D-21-00253.
Osteoporosis is not rare in thoracolumbar spine fusion patients and may portend poorer surgical outcomes. Implementation of a bone health optimization (BHO) clinic improves osteoporosis screening and treatment in the total joint arthroplasty population. We hypothesize that preoperative osteoporosis is common, under-recognized, and undertreated in thoracolumbar fusion patients and that a BHO clinic will increase preoperative osteoporosis screening rates and pharmacologic osteoporosis treatment in this population.
This retrospective case series includes adults older than 30 years who underwent elective thoracolumbar spine fusion at a single tertiary care center before and after creation of a BHO referral clinic. Data collected included preoperative osteoporosis risk factors, prior dual-energy radiograph absorptiometry testing, and prior osteoporosis pharmacotherapy. Fracture risk was estimated using the fracture risk assessment tool with and without bone mineral density (BMD), and the US National Osteoporosis Foundation criteria for screening and treatment were applied.
Ninety patients were included in the pre-BHO group; 53 patients met criteria for BMD measurement, but only 10 were tested within 2 years preoperatively. Sixteen patients (18%) met criteria for osteoporosis pharmacotherapy, but only 5 of the 16 (31%) received osteoporosis medication within 6 months of surgery. There were 87 patients in the post-BHO group, and 19 were referred to the BHO clinic. BMD measurement was done in 17 of the patients (89%) referred to the BHO clinic compared with 10% for those not referred. All patients (n = 7) referred to the BHO clinic meeting treatment criteria received treatment within 6 months before surgery, whereas only 25% of the patients not referred received treatment.
Osteoporosis is not rare in adults undergoing thoracolumbar spine fusion with ∼13% to 18% meeting criteria for pharmacotherapy. Preoperative BHO referral increases screening and treatment.
骨质疏松症在胸腰椎融合患者中并不罕见,可能预示着手术结果较差。实施骨健康优化(BHO)诊所可改善全关节置换人群的骨质疏松症筛查和治疗。我们假设在胸腰椎融合患者中,术前骨质疏松症很常见,但未被充分认识和治疗不足,BHO 诊所将增加该人群的术前骨质疏松症筛查率和药物治疗骨质疏松症。
本回顾性病例系列纳入了在单一三级护理中心接受择期胸腰椎融合术的年龄大于 30 岁的成年人,这些患者在创建 BHO 转诊诊所之前和之后的数据。收集的数据包括术前骨质疏松症危险因素、之前的双能 X 线吸收法检测和之前的骨质疏松症药物治疗。使用骨折风险评估工具(有和无骨密度)评估骨折风险,并且应用美国国家骨质疏松症基金会的筛查和治疗标准。
90 例患者纳入 BHO 前组;53 例符合 BMD 测量标准,但只有 10 例在术前 2 年内进行了检测。16 例(18%)符合骨质疏松症药物治疗标准,但只有 16 例中的 5 例(31%)在手术前 6 个月内接受了骨质疏松症药物治疗。BHO 后组有 87 例患者,19 例被转诊至 BHO 诊所。与未转诊的患者相比,转诊至 BHO 诊所的 17 例患者(89%)进行了 BMD 测量。所有(n=7)转诊至 BHO 诊所且符合治疗标准的患者在手术前 6 个月内接受了治疗,而未转诊的患者中只有 25%接受了治疗。
在接受胸腰椎融合术的成年人中,骨质疏松症并不罕见,约有 13%至 18%符合药物治疗标准。术前 BHO 转诊可增加筛查和治疗。